Invivyd reported that VYD2311 showed superior safety and tolerability compared to an mRNA-based COVID-19 vaccine in its LIBERTY Phase 3 study and plans to submit a Biologics License Application.

Observed price moves

• IVVD+16.69%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.